Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
- Written by PR Newswire
 |
- ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found in up to 40% of tumors
- In patients whose tumors harbor ESR1-mut, a previous post-hoc subgroup analysis...
